69 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2025 TJOAPACK “What helps us is the fact that we have different services that we offer. At Tjoapack Netherlands, we have 20 production lines. 14 of those lines are oral solids, [and] oral solids is about volume,” said Cruz. “So that gives the base for the company to invest on injectables: oral solids bring the large volumes from generic pharma, for instance, and the injectables part is where we deal with specialty pharma and small volumes. It’s complementary, I think the services complement each other and help us to be able to offer this customized service to our clients as well.” In terms of ongoing trends, Cruz felt that the significant growth in injectables was having a discrete impact on contract packaging organizations like Tjoapack. While he was quick to point out that this would not replace oral solids, due to their cost-effectiveness, the increasing affordability of injectors was providing new opportunities to drug manufacturers and patients alike. “The cost of the injectors is going down from the, let’s say, large pharmaceuticals, the mainstream to small pharma,” said Cruz. “It becomes more democratizing...everybody has access to these kinds of drugs, which before were too expensive for the mainstream market. So this, for me, is something that is changing.” GRANT PLAYTER Editor 24/7 BIOPHARMA
RkJQdWJsaXNoZXIy MjY2OTA4MA==